PDE4A and chronic obstructive pulmonary disease: This molecule exhibits potent and selective inhibition activity against phosphodiesterase 4 (PDE4) with a pIC50 of 8.5, thus being a promising target for the treatment of chronic obstructive pulmonary disease (COPD).